Taysha gene therapies reports initial clinical data from first adult rett syndrome patient dosed in reveal phase 1/2 trial and provides corporate update with second quarter 2023 financial results

Data from first adult patient dosed in reveal phase 1/2 trial showed tsha-102 was well-tolerated with no treatment-emergent serious adverse events (saes) as of six-week assessment and improvement in key efficacy measures, including clinical global impression – improvement (cgi-i), clinical global impression – severity (cgi-s) and rett syndrome behavior questionnaire (rsbq), four weeks post-treatment
TSHA Ratings Summary
TSHA Quant Ranking